Tohoku Univ. Technology ：Predictive Markers for the Efficacy of Immune Checkpoint Inhibitors：T25-021
Discovery of a Correlation Between Blood Levels of a Compound and Post-ICI Survival Time
Immune checkpoint inhibitors (ICIs) offer lasting treatment efficacy and improved survival for cancer patients, but positive responses are limited to select individuals and treatment costs are high, highlighting the need to predict benefit before therapy. Current predictive methods like PD-L1 testing mainly measure local tumor tissue expression and fail to fully assess systemic immunity. Researchers examined blood lysophosphatidylcholine (LPC) levels and clinical outcomes after ICI therapy in squamous cell carcinoma patients. They found that those with higher LPC had significantly prolonged survival post-ICI compared to those with lower levels. Because LPC is measurable in blood samples, it reflects systemic immune status and reduces patient burden by eliminating biopsies. This finding supports developing new clinical tests for predicting ICI effectiveness.
- Company：Tohoku Techno Arch Co., Ltd.
- Price：Other
